Home LiteratureArticle Details
PMID: 16200194 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Review

The survival kinases Akt and Pim as potential pharmacological targets.

The Journal of clinical investigation ·Vol. 115 ·No. 10 ·2005-10-00 ·Pages 2618-24

Amaravadi R, Thompson CB

Abstract

The Akt and Pim kinases are cytoplasmic serine/threonine kinases that control programmed cell death by phosphorylating substrates that regulate both apoptosis and cellular metabolism. The PI3K-dependent activation of the Akt kinases and the JAK/STAT-dependent induction of the Pim kinases are examples of partially overlapping survival kinase pathways. Pharmacological manipulation of such kinases could have a major impact on the treatment of a wide variety of human diseases including cancer, inflammatory disorders, and ischemic diseases.

MeSH Terms
Animals Apoptosis/drug effects Cell Survival/drug effects Humans Inflammation/drug therapy,metabolism Ischemia/drug therapy,metabolism Neoplasms/drug therapy,metabolism Phosphorylation/drug effects Protein Kinase Inhibitors/metabolism,therapeutic use Proto-Oncogene Proteins c-akt/antagonists & inhibitors,metabolism Proto-Oncogene Proteins c-pim-1/antagonists & inhibitors,metabolism Signal Transduction/drug effects
Chemicals
Protein Kinase Inhibitors Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-pim-1
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Amaravadi Ravi
Abramson Family Cancer Research Institute, Department of Cancer Biology and Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6160, USA.
Thompson Craig B
References (84)
84 references, click to expand
  1. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades.
    J Biol Chem. 1997 Jul 11;272(28):17269-75 PMID: 9211863
  2. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
    Cell. 1997 Oct 17;91(2):231-41 PMID: 9346240
  3. Regulation of cell death protease caspase-9 by phosphorylation.
    Science. 1998 Nov 13;282(5392):1318-21 PMID: 9812896
  4. Direct control of the Forkhead transcription factor AFX by protein kinase B.
    Nature. 1999 Apr 15;398(6728):630-4 PMID: 10217147
  5. Induction of NF-kappaB by the Akt/PKB kinase.
    Curr Biol. 1999 Jun 3;9(11):601-4 PMID: 10359702
  6. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3.
    Eur J Biochem. 1999 Oct 1;265(1):353-60 PMID: 10491192
  7. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.
    Cancer Res. 2004 Nov 15;64(22):8341-8 PMID: 15548703
  8. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.
    Nature. 2004 Nov 25;432(7016):466-72 PMID: 15565145
  9. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
    Clin Cancer Res. 2004 Nov 15;10(22):7450-6 PMID: 15569974
  10. Integrin-linked kinase expression increases with prostate tumor grade.
    Clin Cancer Res. 2001 Jul;7(7):1987-91 PMID: 11448915
  11. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3.
    Oncogene. 2001 Jul 19;20(32):4419-23 PMID: 11466625
  12. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak.
    Mol Cell. 2004 Dec 3;16(5):819-30 PMID: 15574336
  13. Role of pim-1 in smooth muscle cell proliferation.
    J Biol Chem. 2004 Dec 24;279(52):54742-9 PMID: 15471855
  14. Integrin-linked kinase: a cancer therapeutic target unique among its ILK.
    Nat Rev Cancer. 2005 Jan;5(1):51-63 PMID: 15630415
  15. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.
    Biochem J. 2005 Jan 15;385(Pt 2):399-408 PMID: 15456405
  16. The Pim kinases control rapamycin-resistant T cell survival and activation.
    J Exp Med. 2005 Jan 17;201(2):259-66 PMID: 15642745
  17. Proteasome inhibition as a novel therapeutic target in human cancer.
    J Clin Oncol. 2005 Jan 20;23(3):630-9 PMID: 15659509
  18. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer.
    BMC Cancer. 2005 Jan 5;5:1 PMID: 15631637
  19. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase.
    J Biol Chem. 2005 Feb 18;280(7):6130-7 PMID: 15525646
  20. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
    Science. 2005 Feb 18;307(5712):1098-101 PMID: 15718470
  21. mTOR-targeted therapy of cancer with rapamycin derivatives.
    Ann Oncol. 2005 Apr;16(4):525-37 PMID: 15728109
  22. Akt activation is required at a late stage of insulin-induced GLUT4 translocation to the plasma membrane.
    Mol Endocrinol. 2005 Apr;19(4):1067-77 PMID: 15650020
  23. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
    N Engl J Med. 2005 Mar 17;352(11):1071-80 PMID: 15713944
  24. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3'-kinase is important.
    J Biol Chem. 2005 Apr 8;280(14):14168-76 PMID: 15640155
  25. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.
    J Biol Chem. 2005 Apr 8;280(14):13728-34 PMID: 15657054
  26. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Cancer Cell. 2005 Apr;7(4):387-97 PMID: 15837627
  27. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    N Engl J Med. 2005 Apr 28;352(17):1779-90 PMID: 15858187
  28. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Blood. 2005 May 15;105(10):4021-7 PMID: 15665113
  29. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival.
    Blood. 2005 Jun 1;105(11):4477-83 PMID: 15705789
  30. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
    Blood. 2005 Sep 15;106(6):2162-8 PMID: 15920007
  31. Autophagy in cell death: an innocent convict?
    J Clin Invest. 2005 Oct;115(10):2679-88 PMID: 16200202
  32. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.
    J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32 PMID: 10564676
  33. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
    Nature. 2000 Feb 3;403(6769):503-11 PMID: 10676951
  34. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells.
    Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3207-12 PMID: 10716737
  35. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    N Engl J Med. 2000 Jun 29;342(26):1946-52 PMID: 10874062
  36. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).
    Mol Cell Biol. 2001 Feb;21(3):952-65 PMID: 11154281
  37. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Blood. 2001 Apr 1;97(7):2008-15 PMID: 11264165
  38. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology.
    J Biol Chem. 2001 Apr 13;276(15):12041-8 PMID: 11278698
  39. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta).
    Science. 2001 Jun 1;292(5522):1728-31 PMID: 11387480
  40. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.
    Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603 PMID: 11504915
  41. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
    Cancer Res. 2002 Jun 1;62(11):3132-7 PMID: 12036925
  42. The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
    Nat Rev Cancer. 2002 Jul;2(7):489-501 PMID: 12094235
  43. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake.
    Mol Biol Cell. 2002 Jul;13(7):2276-88 PMID: 12134068
  44. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.
    Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6 PMID: 15046615
  45. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation.
    Cell. 2004 May 14;117(4):421-6 PMID: 15137936
  46. Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells.
    Cell Signal. 2004 Aug;16(8):951-7 PMID: 15157674
  47. Alkylating DNA damage stimulates a regulated form of necrotic cell death.
    Genes Dev. 2004 Jun 1;18(11):1272-82 PMID: 15145826
  48. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.
    Mol Cell Biol. 2004 Jul;24(13):6104-15 PMID: 15199164
  49. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
    Cancer Res. 2004 Jun 15;64(12):4309-18 PMID: 15205346
  50. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
    Cancer Res. 2004 Jul 1;64(13):4394-9 PMID: 15231645
  51. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer.
    Prostate. 2004 Sep 1;60(4):367-71 PMID: 15264249
  52. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.
    FEBS Lett. 2004 Jul 30;571(1-3):43-9 PMID: 15280015
  53. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Leuk Lymphoma. 2004 May;45(5):951-5 PMID: 15291354
  54. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Science. 2004 Aug 20;305(5687):1163-7 PMID: 15284455
  55. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase.
    J Biol Chem. 2004 Sep 24;279(39):41189-96 PMID: 15262962
  56. Deregulated Akt3 activity promotes development of malignant melanoma.
    Cancer Res. 2004 Oct 1;64(19):7002-10 PMID: 15466193
  57. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response.
    Nature. 2004 Oct 21;431(7011):1007-11 PMID: 15496927
  58. The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis.
    Science. 2004 Oct 22;306(5696):695-8 PMID: 15499020
  59. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.
    Cell. 1989 Feb 24;56(4):673-82 PMID: 2537153
  60. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.
    Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 PMID: 1409633
  61. Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor.
    Blood. 1995 Jun 15;85(12):3494-502 PMID: 7540064
  62. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
    Int J Cancer. 1995 Aug 22;64(4):280-5 PMID: 7657393
  63. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
    Cancer Res. 1997 Jun 15;57(12):2452-9 PMID: 9192825
  64. Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription.
    Mol Cell Biol. 2002 Aug;22(16):5962-74 PMID: 12138205
  65. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
    Eur J Cancer. 2002 Aug;38(12):1615-21 PMID: 12142051
  66. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.
    J Biol Chem. 2002 Aug 2;277(31):27613-21 PMID: 12000750
  67. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
    Oncologist. 2002;7 Suppl 3:12-9 PMID: 12165651
  68. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway.
    Mol Cell. 2002 Oct;10(4):721-33 PMID: 12419217
  69. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.
    J Vet Sci. 2001 Dec;2(3):167-79 PMID: 12441685
  70. Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells.
    J Biol Chem. 2003 Feb 21;278(8):5871-82 PMID: 12488318
  71. Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma.
    Virchows Arch. 2003 Feb;442(2):118-23 PMID: 12596061
  72. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Cancer Res. 2003 Mar 15;63(6):1270-9 PMID: 12649187
  73. CH-ILKBP regulates cell survival by facilitating the membrane translocation of protein kinase B/Akt.
    J Cell Biol. 2003 Mar 31;160(7):1001-8 PMID: 12654898
  74. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
    Blood. 2003 Apr 15;101(8):3164-73 PMID: 12468433
  75. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Blood Cells Mol Dis. 2003 Jul-Aug;31(1):11-7 PMID: 12850478
  76. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.
    Genes Dev. 2003 Aug 1;17(15):1841-54 PMID: 12869584
  77. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts.
    Nat Med. 2003 Sep;9(9):1195-201 PMID: 12910262
  78. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death.
    J Biol Chem. 2003 Nov 14;278(46):45358-67 PMID: 12954615
  79. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
    Mol Cancer Ther. 2003 Nov;2(11):1093-103 PMID: 14617782
  80. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival.
    J Biol Chem. 2003 Dec 19;278(51):51324-33 PMID: 14551191
  81. Regulation of tumor angiogenesis by integrin-linked kinase (ILK).
    Cancer Cell. 2004 Jan;5(1):79-90 PMID: 14749128
  82. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.
    Cancer Res. 2004 Mar 1;64(5):1757-64 PMID: 14996737
  83. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.
    Nature. 2004 Mar 18;428(6980):332-7 PMID: 15029198
  84. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes.
    Biochem Soc Trans. 2004 Apr;32(Pt 2):315-9 PMID: 15046598
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI26273
Published
2005-10-00
Pages
2618-24
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC1236693
Subset
IM
Grants
NCI NIH HHS · R25 CA087812 · United States
NCI NIH HHS · R25-CA87812 · United States
External Links
PubMed source DOI: 10.1172/JCI26273 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2